The DOI matches its Crossref record; 79 of the 80 references it cites were found in a registry or an index.
APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
Open accessAbstract
Objective: To examine interactions of apolipoprotein E ( APOE) genotype with age and with in vivo measures of preclinical Alzheimer disease (AD) in cognitively normal aging. Methods: Two hundred forty‐one cognitively normal individuals, aged 45–88 years, had cerebral amyloid imaging studies with Pittsburgh Compound‐B (PIB). Of the 241 individuals, 168 (70%) also had cerebrospinal fluid (CSF) assays of amyloid‐beta 42 (Aβ 42 ), tau, and phosphorylated tau (ptau 181 ). All individuals were genotyped for APOE . Results: The frequency of individuals with elevated mean cortical binding potential (MCBP) for PIB rose in an age‐dependent manner from 0% at ages 45–49 years to 30.3% at 80–88 years. Reduced levels of CSF Aβ 42 appeared to begin earlier (18.2% of those aged 45–49 years) and increase with age in higher frequencies (50% at age 80–88 years) than elevations of MCBP. There was a gene dose effect for the APOE4 genotype, with greater MCBP increases and greater reductions in CSF Aβ 42 with increased numbers of APOE4 alleles. Individuals with an APOE2 allele had no increase in MCBP with age and had higher CSF Aβ 42 levels than individuals without an APOE2 allele. There was no APOE4 or APOE2 effect on CSF tau or ptau 181 . Interpretation: Increasing cerebral Aβ deposition with age is the pathobiological phenotype of APOE4 . The biomarker sequence that detects Aβ deposition may first be lowered CSF Aβ 42 , followed by elevated MCBP for PIB. A substantial proportion of cognitively normal individuals have presumptive preclinical AD. ANN NEUROL 2010;67:122–131
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The association of the APOE4 isoform with amyloid deposition has been well established in human studies, where APOE4 carriers exhibit higher A β plaque burden and earlier onset of amyloid positivity compared with non-carriers 35 -37 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE status has been found to modulate the onset of extracellular amyloid plaque deposition, one of the key pathognomonic features of the disease (6, 7).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“On the basis of previous studies (7, 27), individuals with mean cortical binding potential (MCBP) for PIB >0.18 were considered PIB-positive (PIB+).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Given that a CSF Aβ42 concentration lower than 500 pg/mL has been utilized as a reliable threshold for the presence of cerebral Aβ deposition in humans (7, 19, 22, 26)”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Increasing age and ApoE genetic background are the strongest known risk factors for AD and plaque load (33, 48); thus it was critical that these parameters were controlled.”
From Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans (2011) · cites this paper as [33]
The cited source says what the claim attributes to it.
In the citing paper
“Sex differences in Aβ burden alone have not been reported in older adults,11–13”
From Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults (2019) · cites this paper as [13]
In the citing paper
“Previous cross-sectional studies indicate that Aβ42 levels decrease in the CSF as Aβ starts to accumulate, before fibrillar plaques can be detected with PET7–11.”
From Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity (2017) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Littell, R. C. (1996) · Medical Entomology and Zoology · Cited by 10,345
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Self-citationCorder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Talairach, J., Tournoux, P., & Rayport, M. (1988) · Thieme eBooks · Cited by 5,058
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Flagged first, then by citations
1 of the 80 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 601–700 of 835
Palmer, W. C., Park, S., & Levendovszky, S. R. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.975305 · Cited by 12
A haptoglobin (HP) structural variant alters the effect of APOE alleles on Alzheimer's disease
Bai, H., Naj, A. C., Benchek, P. H., Dumitrescu, L. C., Hohman, T. J., Hamilton‐Nelson, K. L., Kallianpur, A. R., Griswold, A. J., Vardarajan, B. N., Martin, E. R., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13050 · Cited by 11
Shvetcov, A., Thomson, S., Cho, A., Wilkins, H., Reed, J. H., Swerdlow, R. H., Brown, D. A., Initiative, T. A. D. N., & Finney, C. A. (2024) · Aging Cell · doi:10.1111/acel.14439 · Cited by 11
Effect of LXR/RXR agonism on brain and CSF Aβ40 levels in rats
Wang, S., Wen, P. H., & Wood, S. J. (2016) · F1000Research · doi:10.12688/f1000research.7868.2 · Cited by 11
Recent Advances Towards Diagnosis and Therapeutic Fingerprinting for Alzheimer’s Disease
Pradhan, L. K., Sahoo, P. K., Chauhan, S., & Das, S. K. (2022) · Journal of Molecular Neuroscience · doi:10.1007/s12031-022-02009-7 · Cited by 11
The Potential of a Stratified Approach to Drug Repurposing in Alzheimer’s Disease
Anderson, C., Bucholc, M., McClean, P. L., & Zhang, S. (2023) · Biomolecules · doi:10.3390/biom14010011 · Cited by 13
The concept of FDG-PET endophenotype in Alzheimer’s disease
During, E., Osorio, R. S., Elahi, F. M., Mosconi, L., & de Leon, M. J. (2011) · Neurological Sciences · doi:10.1007/s10072-011-0633-1 · Cited by 14
Etnier, J. L., Labban, J. D., Karper, W. B., Wideman, L., Piepmeier, A. T., Shih, C.-H., Castellano, M., Williams, L. M., Park, S.-Y., Henrich, V. C., et al. (2015) · Journal of Aging and Physical Activity · doi:10.1123/japa.2014-0221 · Cited by 12
APOE ε4genotype predicts memory for everyday activities
Bailey, H. R., Sargent, J. Q., Flores, S. E., Nowotny, P., Goate, A., & Zacks, J. M. (2015) · Aging Neuropsychology and Cognition · doi:10.1080/13825585.2015.1020916 · Cited by 12
Self-citationEpistasis analysis links immune cascades and cerebral amyloidosis
Initiative, A. D. N., Benedet, A. L., Labbe, A., Lemay, P., Zimmer, E. R., Pascoal, T. A., Leuzy, A., Mathotaarachchi, S. S., Mohades, S., Shin, M., et al. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0436-z · Cited by 13
Lindberg, O. E., Kern, S., Skoog, J., Machado, A., Pereira, J. B., Sacuiu, S. F., Wahlund, L., Blennow, K., Zetterberg, H., Zettergren, A., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.10.033 · Cited by 10
Petersen, K. K., Grober, E. H., Lipton, R. B., Sperling, R. A., Buckley, R. F., Aisen, P. S. S., & Ezzati, A. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12271 · Cited by 10
Proteomic clusters underlie heterogeneity in preclinical Alzheimer’s disease progression
Wisch, J. K., Butt, O. H., Gordon, B. A., Schindler, S. E., Fagan, A. M., Henson, R. L., Yang, C., Boerwinkle, A. H., Benzinger, T. L. S., Holtzman, D. M., et al. (2023) · Brain · doi:10.1093/brain/awac484 · Cited by 11
Self-citationGenetic influences on cognition in progressive supranuclear palsy
Gerstenecker, A. T., Roberson, E. D., Schellenberg, G. D., Standaert, D. G., Shprecher, D., Kluger, B. M., & Litvan, I. (2017) · Movement Disorders · doi:10.1002/mds.27196 · Cited by 11
The role of pragmatics in the diagnosis of dementia
Cummings, L. (2020) · East Asian Pragmatics · doi:10.1558/eap.39716 · Cited by 9
Pedrero‐Chamizo, R., Zhuang, K., Juarez, A., Janabi, M., Jagust, W. J., & Landau, S. M. (2024) · Journal of science and medicine in sport · doi:10.1016/j.jsams.2024.03.012 · Cited by 12
APOE ɛ4 Genotype, Amyloid, and Clinical Disease Progression in Cognitively Normal Older Adults
Hollands, S., Lim, Y. Y., Laws, S. M., Villemagne, V. L., Pietrzak, R. H., Harrington, K., Porter, T., Snyder, P. J., Ames, D. J., Fowler, C. J., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161019 · Cited by 11
Enlarged perivascular spaces are associated with decreased brain tau deposition
Kang, K. M., Byun, M. S., Yi, D., Lee, K. H., Kim, M. J., Ahn, H., Jung, G., Lee, J., Kim, Y. K., Lee, Y., et al. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14040 · Cited by 9
Detecting amyloid‐β positivity using regions of interest from structural magnetic resonance imaging
Hwang, J., Park, H. K., Yoon, H., Jeong, J. H., Lee, H., & Initiative, A. D. N. (2023) · European Journal of Neurology · doi:10.1111/ene.15775 · Cited by 10
Longitudinal markers of cerebral amyloid angiopathy and related inflammation in rTg-DI rats
Schrader, J. M., Xu, F., Agostinucci, K. J., DaSilva, N. A., & Nostrand, W. E. V. (2024) · Scientific Reports · doi:10.1038/s41598-024-59013-7 · Cited by 11
Haapalinna, F., Kokki, M., Jääskeläinen, O., Hallikainen, M., Helisalmi, S., Koivisto, A. M., Kokki, H. J., Paajanen, T. I., Penttinen, J., Pikkarainen, M., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170534 · Cited by 9
Nuclear Medicine Imaging in Dementia: A Practical Overview for Hospitalists
Toney, L. K., McCue, T. J., Minoshima, S., & Lewis, D. H. (2011) · Hospital Practice · doi:10.3810/hp.2011.08.590 · Cited by 10
Bojar, I., Stasiak, M., Cyniak-Magierska, A., Raczkiewicz, D., & Lewiñski, A. (2016) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000449373 · Cited by 10
Protein intake and episodic memory: the moderating role of the apolipoprotein E ε4 status
Keum, M., Lee, B. C., Choe, Y. M., Suh, G., Kim, S. G., Kim, H. S., Hwang, J., Yi, D., & Kim, J. W. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01546-0 · Cited by 11
Neurodegeneration and the immune system: lessons from autoimmune encephalitis
Campetella, L., Smolik, K., Farina, A., Joubert, B., Muñiz‐Castrillo, S., Desestret, V., & Honnorat, J. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13094-0 · Cited by 12
Neurobiological and therapeutic landmarks of depression associated with Alzheimer’s disease dementia
Untu, I., Davidson, M., Stanciu, G. D., Rabinowitz, J., Dobrin, R., Vieru, D. S., & Tamba, B.-I. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1584607 · Cited by 12
Chuang, Y., Varma, V. R., An, Y., Tanaka, T., Davatzikos, C. A., Resnick, S. M., & Thambisetty, M. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191335 · Cited by 8
Zhang, P.-F., Wang, Z.-T., Liu, Y., Hu, H., Sun, Y., Hu, H.-Y., Ma, Y.-H., Tan, L., & Yu, J.-T. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220057 · Cited by 9
Zhou, M., Xia, X., Yan, H., Li, S., Bian, S., Sha, X., & Wang, Y. (2019) · BioMed Research International · doi:10.1155/2019/4273108 · Cited by 9
Souza‐Talarico, J. N., Perkhounkova, Y., Hein, M., Lee, J., Hefti, M. M., & Sindi, S. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70140 · Cited by 9
Pietzuch, M., Bindoff, A. D., Jamadar, S. D., & Vickers, J. C. (2021) · Scientific Reports · doi:10.1038/s41598-021-93610-0 · Cited by 8
Xu, C., Xiao, D., Su, B., Saveron, J. M., Gamez, D., Navia, R. O., Wang, N., Roy, U., Adjeroh, D., Wang, K., et al. (2023) · Neurological Sciences · doi:10.1007/s10072-023-07076-1 · Cited by 8
Hu, H., Hu, H., Jiang, J., Bi, Y., Sun, Y. P., Ou, Y., Tan, L., & Yu, J. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13837 · Cited by 8
Influence of APOE Genotype on Alzheimer's Disease CSF Biomarkers in a Spanish Population
Argilés, J. A. M., Gasparini-Berenguer, R., Gutiérrez-Agulló, M., Muñoz-Ruiz, C., Sánchez-Payá, J., & Leiva-Santana, C. (2016) · BioMed Research International · doi:10.1155/2016/1390620 · Cited by 9
Molecular Imaging of Extrapyramidal Movement Disorders
Frey, K. A. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.007 · Cited by 8
Polyglucosan Bodies in Aged Brain and Neurodegeneration: Cause or Consequence?
Rai, A., & Ganesh, S. (2019) · Springer eBooks · doi:10.1007/978-981-13-3585-3_4 · Cited by 8
Shaaban, C. E., Tudorascu, D., Glymour, M. M., Cohen, A. D., Thurston, R. C., Snyder, H. M., Hohman, T. J., Mukherjee, S., Yu, L., & Snitz, B. E. (2022) · Frontiers in Neuroimaging · doi:10.3389/fnimg.2022.978350 · Cited by 9
Petersen, K. K., Ezzati, A., Lipton, R. B., Gordon, B. A., Hassenstab, J. J., Morris, J. C., & Grober, E. H. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.98 · Cited by 8
Self-citationRetrogenesis: A Model of Dementia Progression in Alzheimer's Disease Related to Neuroplasticity
Ashford, J. W., & Bayley, P. J. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121124 · Cited by 8
Šutovský, S., Petrovič, R., Fischerová, M., Haverlíková, V., Ukropcová, B., Ukropec, J., & Turčáni, P. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200321 · Cited by 8
A profile of brain reserve in adults at genetic risk of Alzheimer's disease
Coughlan, G., Zhukovsky, P., Voineskos, A. N., & Grady, C. L. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12208 · Cited by 9
Lee, B. C., Choe, Y. M., Suh, G., Choi, I.-G., Lee, J. H., Kim, H. S., Hwang, J., Yi, D., & Kim, J. W. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1065117 · Cited by 9
Rethinking early Alzheimer’s disease: An impaired internal model updating disorder?
Antonioni, A. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106790 · Cited by 8
An optimized method for PCR-based genotyping to detect human APOE polymorphisms
Bonab, L. N. H., Hedayati, M., Fazeli, S. A. S., & DANESHPOUR, M. S. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21102 · Cited by 8
Gao, P., Ou, Y., Huang, Y., Wang, Z., Fu, Y., Ma, Y., Li, Q., Ma, L., Cui, R., Mi, Y., et al. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.16025 · Cited by 7
Pardo, J. V., Lee, J. T., & Initiative, A. D. N. (2018) · eNeuro · doi:10.1523/eneuro.0396-17.2018 · Cited by 8
A Fragment of S38AA is a Novel Plasma Biomarker of Alzheimer’s Disease
Hashimoto, M., Yamazaki, A., Ohno, A., Kimura, T., Winblad, B. G., & Tjernberg, L. O. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190700 · Cited by 7
Aguilar-Pineda, J. A., Paco-Coralla, S. G., Febres-Molina, C., Gamero-Begazo, P. L., Shrivastava, P., Vera-López, K. J., Dávila-Del-Carpio, G., López-Casaperalta, P., Gómez, B., & Cardenas, C. L. L. (2022) · Biomolecules · doi:10.3390/biom12040499 · Cited by 7
Advances in Drug Discovery and Development in Geriatric Psychiatry
Conley, A. C., & NEWHOUSE, P. A. (2018) · Current Psychiatry Reports · doi:10.1007/s11920-018-0871-5 · Cited by 8
Network-constrained technique to characterize pathology progression rate in Alzheimer’s disease
Powell, F., Tosun, D., Raj, A., & Initiative, A. D. N. (2021) · Brain Communications · doi:10.1093/braincomms/fcab144 · Cited by 7
Apolipoprotein E, Neurodegeneration, and Alzheimer Disease
Jagust, W. J. (2012) · JAMA Neurology · doi:10.1001/jamaneurol.2013.726 · Cited by 7
APOE ε2 and presymptomatic stage Alzheimer disease
Caselli, R. J., & Dueck, A. C. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ff94f7 · Cited by 7
Fat and Lipid Metabolism and the Involvement of Apolipoprotein E in Alzheimer's Disease
Hone, E., Lim, F., & Martins, I. J. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch7 · Cited by 8
Sexual dimorphisms in innate immune activation markers in predementia Alzheimer’s disease
Knudtzon, S. L., Nordengen, K., Pålhaugen, L., Gísladóttir, B., Jarholm, J. A., Bråthen, G., Skogseth, R. E., Waterloo, K. K., Selnes, P., Fladby, T., et al. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf161 · Cited by 8
Sex Differences in Alzheimer Disease Imaging Biomarkers in a Diverse, Community-Based Cohort
Akinci, M., Aziz, F., Palta, P., Guzman, D., Cheung, L., Teresi, J. A., Brickman, A. M., Lao, P. J., & Luchsinger, J. A. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.54524 · Cited by 6
Vascular Heparan Sulfate and Amyloid-β in Alzheimer’s Disease Patients
McMillan, I. O., Gearing, M., & Wang, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073964 · Cited by 7
Xue, R., Gao, P., Chen, Y.-M., Liu, Y., Han, B., Huang, Y., Mi, Y., Cui, R., Lin, Y., Wang, Z.-T., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251322808 · Cited by 6
Targeting apolipoprotein E for treating Alzheimer’s disease
Bales, K. R., & Paul, S. M. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134366 · Cited by 7
Apolipoprotein E e4 allele status and later-life depression in the Lothian Birth Cohort 1936
Iveson, M. H., Taylor, A. M., Harris, S. E., Deary, I. J., & McIntosh, A. M. (2021) · Psychological Medicine · doi:10.1017/s0033291721000623 · Cited by 6
Brichko, R., Soldan, A., Zhu, Y., Wang, M., Faria, A. V., Albert, M., & Pettigrew, C. A. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.859826 · Cited by 6
APOE Is Associated With Serum Tau Following Uncomplicated Mild Traumatic Brain Injury
Lippa, S. M., Lange, R. T., Dalgard, C. L., Soltis, A. R., Guedes, V. A., Brickell, T. A., French, L. M., & Gill, J. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.816625 · Cited by 7
Forno, G., Contador, J., Pérez‐Millan, A., Guillén, N., Falgàs, N., Sarto, J., Tort‐Merino, A., Castellví, M., Bosch, B., Fernández‐Villullas, G., et al. (2022) · European Journal of Neurology · doi:10.1111/ene.15657 · Cited by 7
The association of microbial infection and adaptive immune cell activation in Alzheimer’s disease
Clement, M. (2023) · Discovery Immunology · doi:10.1093/discim/kyad015 · Cited by 6
Mast, B. T. (2012) · Clinical Gerontologist · doi:10.1080/07317115.2012.702647 · Cited by 6
Lifespan brain activity, b-amyloid, and Alzheimer's disease
Jagust, W. J., & Mormino, E. C. (2011) · Cited by 6
Prospective Memory: Age related change is influenced by APOE genotype
Lancaster, C. L., McDaniel, M. A., Tabet, N., & Rusted, J. M. (2019) · Aging Neuropsychology and Cognition · doi:10.1080/13825585.2019.1671305 · Cited by 7
Ho, S. H., & Yang, D. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200439 · Cited by 6
Goto, M., Kimura, N., & Matsubara, E. (2022) · Psychogeriatrics · doi:10.1111/psyg.12825 · Cited by 6
Mozersky, J. T., AGREED, O. B. O., Roberts, J. S., Rumbaugh, M. C., Chhatwal, J. P., Wijsman, E. M., Galasko, D. R., & Blacker, D. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220113 · Cited by 6
Fatima, T., Jacobsson, L., Kern, S., Zettergren, A., Blennow, K., Zetterberg, H., Johansson, L. H., Dehlin, M., & Skoog, I. G. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12241 · Cited by 5
Klunk, W. E., & Perani, D. (2013) · Neurology · doi:10.1212/01.wnl.0000435568.38352.2e · Cited by 6
The Role of Genetics in Alzheimer's Disease and Parkinson's Disease
Porter, T., Gozt, A., Mastaglia, F. L., & Laws, S. M. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch15 · Cited by 6
Gonneaud, J., Baria, A. T., Binette, A. P., Gordon, B. A., Chhatwal, J. P., Cruchaga, C., Jucker, M., Levin, J., Salloway, S., Farlow, M. R., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.06.076745 · Cited by 6
Self-citationBackwaters and rapids on the amyloid river
Burns, J. M., & Swerdlow, R. H. (2013) · Neurology · doi:10.1212/wnl.0b013e3182840d14 · Cited by 5
Waqar, Z., Sethi, P., Jain, D., Singh, K., Alsaidan, O. A., Alzarea, S. I., Gupta, J. K., Saxena, S., & Sharma, M. C. (2025) · Current Genomics · doi:10.2174/0113892029372437251010114053 · Cited by 6
Molecular and Therapeutic Targets for Amyloid-beta Plaques in Alzheimer's Disease: A Review Study
Thomas, J., & WILSON, S. K. (2021) · Basic and Clinical Neuroscience Journal · doi:10.32598/bcn.2021.3522.1 · Cited by 6
Bello-Corral, L., Seco‐Calvo, J., Fresno, Á. M., González, A. I., Llorente, A. M., Fernández‐Lázaro, D., & Sánchez-Valdeón, L. (2024) · Medicina · doi:10.3390/medicina60121941 · Cited by 6
Potential molecular mechanisms of tobacco smoke exposure in Alzheimer’s disease
Xie, Y., Yang, M., Wang, H., Chen, Y., Shi, X., Tang, H., & Sun, Q. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149394 · Cited by 6
Tian, G., Hanfelt, J., Lah, J., & Risk, B. B. (2024) · Data Science in Science · doi:10.1080/26941899.2024.2309403 · Cited by 5
Wu, J., Wang, J., Xiao, Z., Lu, J., Ma, X., Zhou, X., Wu, Y., Liang, X., Zheng, L., Ding, D., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcaf015 · Cited by 6
Genetic Variants and Related Biomarkers in Sporadic Alzheimer’s Disease
Guerreiro, R. J., Brás, J., Toombs, J., Heslegrave, A., Hardy, J., & Zetterberg, H. (2014) · Current Genetic Medicine Reports · doi:10.1007/s40142-014-0062-6 · Cited by 6
First, M. B., Carter, C., Castellanos, F. X., Dickstein, D. P., Drevets, W. C., Kim, K. L., Pescosolido, M. F., Rausch, S., Seymour, K. E., & Zubieta, J.-K. (2012) · Cited by 5
Luckett, E. S., Schaeverbeke, J. M., Meyer, S. D., Adamczuk, K., Laere, K. V., Dupont, P. J., & Vandenberghe, R. R. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2023.103321 · Cited by 5
Seo, D., Do, A. N., Heo, G., Kwon, J., Song, S., Apio, C., Lee, C. M., Timsina, J., Gong, K., Chen, Y., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00971-6 · Cited by 10
Self-citationLiu, Y., Initiative, A. D. N., Wang, X.-J., Tan, L., Tan, C., & Xu, W. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230516 · Cited by 5
Xing, F., Meng, T., Therriault, J., Luo, J., Zhang, H., & Initiative, A. D. N. (2021) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2002027 · Cited by 4
Chockanathan, U., & Padmanabhan, K. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15636 · Cited by 6
Park, D. C., & Farrell, M. E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-411469-2.00005-4 · Cited by 4
Williams, E., Mutlu-Smith, M., Alex, A., Chin, X. W., Spires‐Jones, T. L., & Wang, S. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221185 · Cited by 5
Aβ Imaging in Aging, Alzheimer’s Disease and Other Neurodegenerative Conditions
Villemagne, V. L., Fodero‐Tavoletti, M. T., Yates, P. A., Masters, C. L., & Rowe, C. C. (2014) · Springer eBooks · doi:10.1007/978-3-642-54307-4_10 · Cited by 4
Does an Alzheimer's disease susceptibility gene influence the cognitive effects of cancer therapy?
Caselli, R. J. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24768 · Cited by 4
Associating Cognition With Amyloid Status Using Partially Ordered Set Analysis
Carr, S. J. A., Jaeger, J., Bian, S., He, P., Maserejian, N. N., Wang, W., Maruff, P. T., EnayetAllah, A. E., Wang, Y., Chen, Z., et al. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00976 · Cited by 4
Farias, F., Benítez, B. A., & Cruchaga, C. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105247 · Cited by 4
APOE4 Increases Susceptibility to Amyloid, Accelerating Episodic Memory DeclinePreprint
Vanderlip, C. R., Stark, C. E. L., & Initiative, T. A. D. N. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.23.630203 · Cited by 4
Li, W., Fan, D., Sun, Q., Wang, L., Huang, B., Yu, Z., Tian, D., Shen, Y., Tan, C., Zeng, G., et al. (2025) · Aging Cell · doi:10.1111/acel.70036 · Cited by 3
Spatial patterns of tau accumulation across the Alzheimer's disease spectrum
Fonseca, C. S., Chao, Y., Joie, R. L., Rabinovici, G. D., Jagust, W. J., Harrison, T. M., & Initiative, A. D. N. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71076 · Cited by 3
Wijesinghe, P., Wijeweera, G., & de Silva, K. R. D. (2023) · Healthy ageing and longevity · doi:10.1007/978-3-031-22468-3_7 · Cited by 3
alzheimer disease: New Concepts on Its Neurobiology and the Clinical
Jack, C. R., & Cme, O. (2012) · Cited by 3
Rohn, T. T., Beck, J. D., Galla, S. J., Isho, N. F., Pollock, T. B., Suresh, T., Kulkarni, A., Sanghal, T., & Hayden, E. J. (2021) · International Journal of Neurodegenerative Disorders · doi:10.23937/2643-4539/1710020 · Cited by 3
Manganese level and cognitive decline in older adults with the APOE e4 allele: a preliminary study
Kim, S. G., Choe, Y. M., Suh, G., Lee, B. C., Choi, I.-G., Kim, H. S., Hwang, J., Keum, M., Yi, D., & Kim, J. W. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115403 · Cited by 3
Metadata
- Authors
- Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Morris, John C.
- ORCID
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2010-01
- Volume
- 67
- Issue
- 1
- Pages
- 122-131
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- PMC
- PMC2830375
- OpenAlex
- W2014897304
- Cited by
- 830
- References
- 80
- Citations by year
- 2026: 21 · 2025: 23 · 2024: 38 · 2023: 39 · 2022: 54 · 2021: 40 · 2020: 53 · 2019: 53 · 2018: 49 · 2017: 58 · 2016: 54 · 2015: 48 · 2014: 65 · 2013: 76 · 2012: 63
- FWCI
- 32.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000448)
- National Institute on Aging (P50AG005681, P01AG003991, P01AG026276)
- National Center for Research Resources (UL1RR024992)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- apolipoprotein E, APOE ε4, APOE2, amyloid-beta, tau protein, preclinical Alzheimer's disease, Pittsburgh compound B, cerebrospinal fluid biomarkers, gene dosage effect, phosphorylated tau
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alzheimer Disease, Aniline Compounds, Apolipoproteins E, Brain, Female, Follow-Up Studies, Genotype, Humans, Longitudinal Studies, Male, Middle Aged, Peptide Fragments, Phosphorylation, Thiazoles, Amyloid beta-Peptides, tau Proteins, Apolipoprotein E4, Apolipoprotein E2, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
